LASSO network analysis identifies shared cancer RNA associations
Source check: Source checked. Not independent scientific confirmation.
Finding: Cancerin integrated expression, copy number, methylation and transcription-factor data to infer competing-endogenous-RNA associations across four hormone-dependent cancer groups in TCGA. BUB1, EXO1 and RRM2 appeared in shared networks and were associated with survival in specified cross-cancer combinations. These are retrospective computational associations; the study did not experimentally establish RNA competition or causal regulatory mechanisms.
Technology: Cancerin; LASSO
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- LASSO selects expression regulators while considering copy number, methylation and transcription factors; subsequent statistics infer shared candidate RNA networks.
- Test and result
- Repeated LASSO selection with bootstrap confidence intervals, inferred network associations and retrospective TCGA survival checks.
- Limitation / still unknown
- Independent cohort confirmation and experimental regulatory/causal validation remain unestablished.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9542250/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary full paper relevant model Methods, study Results and limitations; exact primary front-matter identity and Europe PMC metadata checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.